Sonoma Pharmaceuticals

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals traces its lineage to 2004, when it was incorporated as Oculus Innovative Sciences, later rebranding to reflect its focus on hypochlorous acid chemistries. CEO Amy Trombly oversees a micro-cap public entity that manufactures prescription dermatology, eye care, and wound management products. The underlying technology platform relies on the body's own antimicrobial defense molecule to treat a range of conditions without inducing antibiotic resistance. Strategy centers on direct commercialization and global distribution partnerships rather than fund allocations. Product lines include prescription dermatologics, over-the-counter consumer gels, and animal health solutions sold through distributors in Europe, Asia, and Latin America. Confirmed revenue-generating geographies include the United States, Mexico, China, and the European Union. The company maintains manufacturing operations in the United States and Latin America, and entered a supply agreement with Teva Pharmaceuticals for a dermatology product, as disclosed in corporate filings (per the firm's official communications). Scale remains modest. The company reports revenue in the low tens of millions of dollars and employs a lean operational team across Boulder, Colorado, and its Mexican manufacturing subsidiary. A April 2024 SEC filing noted the company is expanding its over-the-counter consumer product line into national pharmacy chains across the United States. There are no disclosed adjacent private investment vehicles, foundations, or family office structures. Structurally, Sonoma is an anomaly in an Altss context — it is a publicly traded operating company, not an allocator or private investment firm. Its presence in a family-office database likely stems from classification artifacts. It has no disclosed pool of third-party capital, no investment committee, and no co-investment structure. For any institutional allocator evaluating it as a GP, the correct posture is to recognize it as a commercial entity outside the investment-manager universe.